Difference between revisions of "Galeterone (TOK-001)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Antiandrogen with multiple mechanisms of action: androgen receptor inhibitor (ARI), androgen biosynthesis inhibitor (CYP17 inhibitor), and accelerates degradation of the androgen receptor. | + | Class/mechanism: Antiandrogen with multiple mechanisms of action: androgen receptor inhibitor (ARI), androgen biosynthesis inhibitor (CYP17 inhibitor), and accelerates degradation of the androgen receptor. Galeterone is believed to decrease prostate cancer proliferation and trigger cell death by interfering with testosterone-mediated pathways and signaling mechanisms used by prostate cancer cells.<ref>Robert B. Montgomery, Mario A. Eisenberger, Elisabeth I. Heath, A. Oliver Sartor, Franklin Chu, Neal D. Shore, William Jeffery Edenfield, Alan J. Koletsky, David Uri Lipsitz, James S. Cochran, Luke T. Nordquist, Jennifer Roberts, Mary-Ellen Taplin. Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study. 2014 ASCO Annual Meeting abstract 5029. [http://meetinglibrary.asco.org/content/135176-144 link to abstract]</ref><ref>[http://www.ascopost.com/ViewNews.aspx?nid=20590 Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer] The ASCO Post, 11/19/2014</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Patient drug information== | ==Patient drug information== | ||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' AR-V7, VN/124-1 | + | *'''Code names:''' AR-V7, TOK-001, VN/124-1 |
==References== | ==References== | ||
| Line 18: | Line 18: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:Steroidal androgen receptor inhibitors]] | [[Category:Steroidal androgen receptor inhibitors]] | ||
| − | [[Category: | + | [[Category:CYP17 inhibitors]] |
[[Category:Halted drugs]] | [[Category:Halted drugs]] | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Antiandrogen with multiple mechanisms of action: androgen receptor inhibitor (ARI), androgen biosynthesis inhibitor (CYP17 inhibitor), and accelerates degradation of the androgen receptor. Galeterone is believed to decrease prostate cancer proliferation and trigger cell death by interfering with testosterone-mediated pathways and signaling mechanisms used by prostate cancer cells.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Patient drug information
No information available.
Also known as
- Code names: AR-V7, TOK-001, VN/124-1
References
- ↑ Robert B. Montgomery, Mario A. Eisenberger, Elisabeth I. Heath, A. Oliver Sartor, Franklin Chu, Neal D. Shore, William Jeffery Edenfield, Alan J. Koletsky, David Uri Lipsitz, James S. Cochran, Luke T. Nordquist, Jennifer Roberts, Mary-Ellen Taplin. Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study. 2014 ASCO Annual Meeting abstract 5029. link to abstract
- ↑ Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer The ASCO Post, 11/19/2014